An Efficient Route to Novel 2-(Salicylmethylidine)imidazolidines and (Salicylmethylidene)hexahydropyrimidines through Reactions of 2-(N-Methylanilino)-3-formylchromone with Aliphatic Diamines

Gurmit  Singh; Gurpinder  Singh; M. P. S.  Ishar

doi:10.1055/s-2003-36780

LETTER

An Efficient Route to Novel 2-(Salicylmethylidine)imidazolidines and (Salicylmethylidene)hexahydropyrimidines through Reactions of 2-(N-Methylanilino)-3-formylchromone with Aliphatic Diamines

Gurmit Singh, Gurpinder Singh, M. P. S. Ishar*
Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar - 143005, Punjab, India
Fax: +91(183)258820; e-Mail: mpsishar@rediffmail.com;

Abstract

All articles of this category

Abstract

Contrary to the reactions of 2-(N-methylanilino)-3-formylchromones (3) with aliphatic/aromatic primary amines, including o-phenylenediamine, which involve nucleophilic substitution at C2 and/or condensation with the 3-formyl function, the reactions of 3 with aliphatic diamines such as ethylenediamine and 1,3-diaminopropane proceed through sequential attack by both amino functions at C2 in 3. The latter reactions afford, through nucleophilic substitution of the N-methylanilino moiety followed by chromone ring opening, novel potentially biologically active, 2-(formyl-salicyl-methylidene)imidazolidines (7a-c) and 2-(formyl-salicyl-methylidene)hexahydropyrimidines (7d-f) in high yields.

Key words

imidazolidines - hexahydropyrimidines - chromones - nucleophilic substitution - diamines

Full Text

References

1a Silverman RB. In Organic Chemistry of Drug Design and Drug Action Academic Press Inc.; San Diego: 1992. Chap. 2. p.4-50

1b Comprehensive Medicinal Chemistry Vol. 4: Hansch C. Sammes PG. Taylor JB. Pergamon Press; London: 1990.

1c Musser JH. In Medicinal Chemistry for the 21st Century Wermuth CG. Blackwell Scientific Publications; Oxford: 1992. p.25-38

1d Austel V. In Modern Drug Research Martin YC. Kutter E. Austel V. Marcell Dekker; New York: 1989. p.243-307

1e Burger A. In Burgers Medicinal Chemistry and Drug Discovery 5th ed.,Vol. 1: Wolf ME. John Wiley and Sons; New York: 1996. Chap. 1. p.3-8

2a Thompson LA. Ellman JA. Chem. Rev. 1996, 96: 555

2b Fruchtel JS. Jung G. Angew. Chem., Int. Ed. Engl. 1996, 35: 17

2c Nezfi A. Ostresh JM. Houghten RA. Chem. Rev. 1997, 97: 449

2d Robert GF. J. Comb. Chem. 2000, 2: 195

3a Comprehensive Medicinal Chemistry Vol. 6.: Hansch C. Sammes PG. Taylor JB. Pergamon Press; London: 1990.

3b Lednicer D. Strategies for Organic Drug Synthesis and Design John Wiley and Sons; New York: 1998. p.185-241

3c Timmerman PBM. Smith RD. In Burgers Medicinal Chemistry and Drug Discovery 5th ed.,Vol. 2: Wolf ME. John Wiley and Sons; New York: 1996. p.265-321

3d Michael MC. Schafers R. J. Cardiovasc. Pharmacol. 1992, 29 (Suppl .4): S24

3e Safar ME. Am. J. Med. 1989, 87 (Suppl. 3C): 24S

3f Robinson CP. Drugs Today 1988, 24: 557

3g Timmerman PBM. Van Zwieten PA. Eur. J. Med. Chem. 1980, 15: 233

3h Houston MC. Prog. Cardiovasc. Dis. 1981, 23: 337

3i Stump DC. Macfarlane DE. J. Lab. Clin. Biol. Res. 1983, 102: 779

3j U’Prichard DC. Prog. Clin. Biol. Res. 1981, 71: 53

3k Rout B. Leclerc G. Bull. Soc. Chim. Fr. 1979, 520

3l Haron DWG. Shank RG. Lancet 1981, 1: 351

3m Haron DWG. Shank RG. Eur. Heart J. 1985, 6: 722

3n Heidenreich O. Fuelgraff G. Baumeister L. Schmiz K. Arch. Expt. Pathol. Pharmakol. 1964, 249: 432

3o Heidenreich O. Baumeister L. Fuelgraff G. Keller P. Kook Y. Arch. Int. Pharmadyn. 1965, 156: 348

3p Outt PE. Ares JJ. Roberts GE. Wang X. Cupps TL. Wireko FC. J. Org. Chem. 1998, 63: 5762

3q Rosatti GF. Polleto MG. Farmaco 1966, 21: 204

3r Campbell WR. Polter DE. Prog. Neuro Psych. Biol. Psych. 1994, 18: 1051

3s Peckkhold JC. Curr. Ther. Res. 1980, 27: 111

4a Timmerman PBM. Van Zwieten PA. J. Med. Chem. 1977, 20: 1636

4b Timmerman PBM. Van Zwieten PA. Eur. J. Med. Chem. 1980, 15: 233

4c Velly J. J. Pharmacol. 1977, 8: 351

4d Kamitani T. Kamamoto M. Truzioka K. Terai T. Minovu O. Ono T. Kikuchi K. Kumada S. Jpn. J. Pharmacol. 1985, 39: 251

4e Biedermann J, Borbe H, Graf E, Hirlboll G, and Prop G. inventors; German Patent . DE 3,407.509; Chem. Abstr., 1986, 104, 15084v

5 Yu Y. Ostresh JM. Houghten RA. J. Org. Chem. 2002, 67: 3138

6a Ishar MPS. Kumar K. Singh R. Tetrahedron Lett. 1998, 39: 6547

6b Ishar MPS. Kumar K. Tetrahedron Lett. 1999, 40: 175

6c Ishar MPS. Singh G. Kumar K. Singh R. Tetrahedron 2000, 56: 7817

6d Singh G. Singh R. Girdhar NK. Ishar MPS. Tetrahedron 2002, 58: 2471

6e

Singh, G.; Singh, L.; Ishar, M. P. S. Tetrahedron 2002, 58, in press.

7

General Procedure for Reactions of 2-( N -Methyl-anilino)-3-formylchromones (3a-c) with Aliphatic Diamines (Ethylenediamine and 1,3-Diaminopropane): 2-(N-Methylanilino)-3-formylchromones (3a-c, 1.0 mmol) were dissolved in acetonitrile-water (80:20, 50 mL) at reflux and the solutions of diamines (1.0 mmol) in acetonitrile (5 mL) were added to the above solutions. The contents were heated at reflux for 2 h, after which the solvent was evaporated under vacuum. The crude products were directly crystallized and recrystallized from acetone.

8a

2-(Formyl-salicyl-methylidene)imidazolidine (7a): Colorless crystalline solid, mp 265-266 °C (acetone). UV (MeOH): 362.4, 263, 228.4 nm. IR (KBr): 3310 (s), 3118 (b), 1672 (HC=O), 1625 (C=O), 1602, 1533, 1452, 1434
cm^-1. ¹H NMR (200 MHz, DMSO-d ₆): δ = 9.18 (overlapping singlets, 2 H, NH, OH), 8.94 (s, 1 H, HC=O), 8.30 (s, 1 H, NH), 7.22 (dt, 1 H, J = 8.61, 2.35 Hz, C4′-H), 7.03 (dd, 1 H, J = 8.29 Hz, 1.69, C6′-H), 6.80-6.76 (m, 2 H, C3′-H and C5′-H), 3.63 (s, 4 H, N-CH₂ × 2). MS: m/z (%) = 230 (1) [M⁺ - 2], 214 (1.5), 213 (3), 205 (5), 204 (29), 203 (8), 84 (100), (Found: C, 62.28; H, 5.11; N, 12.34. C₁₂H₁₂N₂O₃ requires C, 62.06; H, 5.21; N 12.06 %).
2-[(5-Chlorosalicyl)-formyl-methylidene]imidazolidine (7b): Colorless crystalline solid, mp 271-272 °C (acetone). UV (MeOH): 262, 223 nm. IR (KBr): 3350 (b), 3100 (b), 1668 (HC=O), 1619 (C=O), 1595, 1556, 1532, 1541 cm^-1. ¹H NMR (300 MHz, DMSO-d ₆): δ = 9.75 (br s, 1 H, OH), 9.21 (br s, 2 H, NH × 2), 9.10 (s, 1 H, CHO), 7.15 (dd, 1 H, J = 8.61, 2.35 Hz, C4′-H), 7.08 (d, 1 H, J = 2.30 Hz, C6′-H), 6.85 (d, 1 H, J = 8.69 Hz, C3′-H), 3.77 (s, 4 H, N-CH₂ × 2). ¹³C NMR (75 MHz, DMSO-d ₆): δ = 190.43 (C=O), 188.06 (CHO), 163.43 (C2), 152.69 (C2), 129.72 (C1′), 129.31 (CH), 127.67 (CH), 122.59 (C5′), 117.25 (CH), 99.65 (quat.), 42.43 (N-CH₂). Mass (FAB⁺): m/z (%) = 269 (31) [(M + H)⁺ + 2 (³⁷Cl)], 268 (22) [(M + H)⁺ + 1], 267 (100) [(M + H)⁺ for ³⁵Cl], 266 (36), 249 (37), 155 (18), 154 (93), 140 (30), 139 (24), 138 (45), 137 (68), (Found: C, 53.87; H, 4.01; N, 10.81. C₁₂H₁₁N₂O₃Cl requires C, 54.05; H, 4.16; N 10.50%].
2-[Formyl-(5-Methylsalicyl)-methylidene]imidazolidine (7c): Colorless crystalline solid, mp 267-269 °C (acetone). UV (CHCl₃): 324, 287, 267.5, 256 nm. IR (KBr): 3290 (b), 3060 (b), 1660 (HC=O), 1622 (C=O), 1580, 1520, 1500, 1428, 1392, 1378, 1331, 1288, 1261 cm^-1. ¹H NMR (200 MHz, CDCl₃-DMSO-d ₆, 8:2): δ = 9.75 (br s, 1 H, -OH), 9.33 (s, 1 H, CHO), 9.24 (br s, 2 H, NH × 2), 7.10-7.06 (m, 2 H, arom.-Hs), 6.80 (d, 1 H, J = 8.09 Hz, C3′-H), 3.82 (s, 4 H, N-CH₂ × 2), 2.26 (s, 3 H, Ar-CH₃). MS: m/z (%) = 245 (8) [M⁺ - 1], 243 (9), 188 (11), 169 (100), 111 (60), 94 (41), 83 (47), 71 (78), (Found: C, 63.18; H, 5.51; N, 11.64. C₁₃H₁₄N₂O₃ requires C, 63.40; H, 5.73; N 11.38%).
2-(Formyl-salicyl-methylidene)hexahydropyrimidine (7d): Colorless crystalline solid (219 mg, 89%), mp 176-177 °C (acetone). UV (MeOH): 332, 262.5, 219 nm. IR (KBr): 3400 (b), 3090 (b), 2755, 1656 (HC=O), 1642 (C=O), 1604, 1572, 1401, 1365, 1338, 1326, 1302, 1273, 1245, 1224, 1147 cm^-1: ¹H NMR (200 MHz, DMSO-d ₆): δ = 10.64 (br s, 2 H, NH and OH), 9.83 (br s, 1 H, NH), 9.13 (s, 1 H, CHO), 7.37 (dt, 1 H, J = 7.02, 1.51 Hz, C4′-H), 7.24 (br d, 1 H, J = 6.42 Hz, C6′-H), 7.07-6.99 (m, 2 H, C5′-H and C3′-H), 3.61 (b, 4 H, N-CH₂ × 2), 2.13-2.08 (m, 2 H, -CH₂). ¹³C NMR (50 MHz, DMSO-d ₆): δ = 194.25 (C=O), 189.70 (CHO), 158.82 (C2), 153.70 (C2′), 130.10 (CH), 128.98 (C1′), 128.80 (CH), 119.25 (CH), 115.80 (CH), 100.51 (quat.), 37.78 (N-CH₂), 19.06 (CH₂). MS: m/z (%) = 246 (15) [M⁺], 228 (69) [M⁺ - 18], 172 (42), 108 (100), (Found: C, 63.26; H, 5.48; N, 11.11. C₁₃H₁₄N₂O₃ requires C, 63.40; H, 5.73; N 11.38%).
2-[(5-Chlorosalicyl)-formyl-methylidene]hexahydro-pyrimidine (7e): Colorless crystalline solid, mp 169-171 °C (acetone). UV (CHCl₃): 330, 269.5, 251 nm. IR (KBr): 3490 (b), 3100 (b), 1657 (HC=O), 1635 (C=O), 1611, 1535, 1468, 1430, 1418, 1358, 1322, 1282, 1260, 1240, 1215 cm^-1. ¹H NMR (200 MHz, CDCl₃-DMSO-d ₆, 8:2): δ = 10.46 (br, 2 H, NHs), 9.02 (s, 1 H, CHO), 7.28-7.01 (m, 2 H, arom.-Hs), 6.80 (d, 1 H, J = 8.58 Hz, C3′-H), 3.44-3.41 (m, 4 H, N-CH₂ × 2), 2.00-1.93 (m, 2 H, -CH₂). MS: m/z (%) = 282 [(M⁺ + 2 (³⁷Cl)], 281 (1.9), 280 (10)[M⁺ (³⁵Cl)], 279 (35), 264 (8), 262 (31), 254 (14), 252 (30), 247 (5), 246 (3), 245 (18), 152 (4), 150 (18), 172 (5), 171 (23), 169 (70), 99 (15), 98 (100), 97 (14), (Found: C, 55.84; H, 4.81; N, 9.63. C₁₃H₁₃N₂O₃Cl requires C, 55.62; H, 4.67; N, 9.98%).
2-[Formyl-(5-methylsalicyl)-methylidene]hexahydro-pyrimidine (7f): Creamy yellow crystalline solid, mp 160-162 °C (acetone). UV (CHCl₃): 332, 307, 271.5, 256.5 nm. IR (KBr): 3360 (b), 3040 (b), 1658 (HC=O), 1633 (C=O), 1606, 1571, 1470, 1451, 1390, 1361, 1280 cm^-1. ¹H NMR (200 MHz, CDCl₃): δ = 10.51 (br, 2 H, NHs), 9.35 (s, 1 H, CHO), 7.14-7.08 (m, 2 H, arom -Hs), 6.84 (d, 1 H, J = 8.26 Hz, C3′-H), 3.48-3.41 (s, 4 H, N-CH₂ × 2), 2.24 (s, 3 H, Ar-CH₃), 2.05-1.97 (m, 2 H, CH₂). ¹³C NMR (50 MHz, CDCl₃): δ = 196.66 (C=O), 189.78 (CHO), 159.99 (C2), 156.83 (C2′), 133.41 (CH), 131.71 (CH), 127.11 (C1′), 122.16 (C5′), 117.11 (CH), 100.06 (quat.), 37.81 (N-CH₂), 20.41 (Ar-CH₃), 19.20 (CH₂). MS: m/z (%) = 260 (20) [M⁺], 259 (18), 169 (91), 111 (76), 83 (49), 71 (100), (Found: C, 64.28; H, 5.96; N, 10.99. C₁₄H₁₆N₂O₃ requires C, 64.60; H, 6.20; N 10.76%).

8b Jackman LM. Timothy F. J. Am. Chem. Soc. 1975, 97: 2811